P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

Bibliographic Details
Main Authors:	Balint JP, Yoshida LH, Xu Y, Gabitzsch ES, Amalfitano A, Jones FR
Format:	Article
Language:	English
Published:	BMC 2009-10-01
Series:	Retrovirology

Similar Items

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
by: Kathryn L Hopkins, et al.
Published: (2014-01-01)

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.
by: Zabrina L Brumme, et al.
Published: (2009-08-01)

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins
by: Brumme, Zabrina L., et al.
Published: (2010)

Functional association between the nef gene product and gag-pol region of HIV-1.
by: Ono, Takeshi
Published: (2014)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
by: Gloria Omosa-Manyonyi, et al.
Published: (2015-01-01)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
by: Wagner R, et al.
Published: (2009-10-01)

Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice
by: Schuldt Nathaniel J, et al.
Published: (2012-06-01)

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
by: Holly Janes, et al.
Published: (2012-01-01)

Improving Adenovirus Based Gene Transfer: Strategies to Accomplish Immune Evasion
by: Andrea Amalfitano, et al.
Published: (2010-09-01)

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial
by: Frahm N, et al.
Published: (2009-10-01)

Assembly of HIV-1 Gag-Pol
by: Ting-Wei Guo, et al.
Published: (2015)

Immune recognition of Gene Transfer Vectors: Focus on Adenovirus as a paradigm
by: Andrea eAmalfitano, et al.
Published: (2011-09-01)

Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with <it>gag</it>, <it>tat</it>, <it>rev</it> and <it>nef</it> mRNA
by: Nijs Griet, et al.
Published: (2011-10-01)

HIV Pol inhibits HIV budding and mediates the severe budding defect of Gag-Pol.
by: Xin Gan, et al.
Published: (2012-01-01)

Human adenovirus serotype 5 vaccines : routes of delivery and formulations for successful immunization
by: Dekker, Joseph Dylan
Published: (2010)

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
by: Aseem Pandey, et al.
Published: (2012-01-01)

Intracellular inhibition of immune dysfunction induced by HIV-I NEF protein
by: Chang, Alex Hongsheng
Published: (2009)

Intracellular inhibition of immune dysfunction induced by HIV-I NEF protein
by: Chang, Alex Hongsheng
Published: (2009)

Determination of the relative amounts of Gag and Pol proteins in foamy virus particles
by: Herchenröder Ottmar, et al.
Published: (2005-07-01)

N-myristoyltransferase1 and N-myristoyltransferase2 Exhibit Differential Substrate Specificity for HIV-Gag and HIV-Nef
by: Smith Charles, et al.
Published: (2005-12-01)

HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag
by: Fu-Hsien Yu, et al.
Published: (2020-01-01)

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
by: Anna Figueiredo, et al.
Published: (2006-11-01)

Untersuchungen zum Gag- und Pol-Protein des Prototypischen Foamyvirus (PFV)
by: Cartellieri, Marc
Published: (2006)

Control of gag-pol gene expression in the Candida albicans retrotransposon Tca2
by: Forbes, Elaine, et al.
Published: (2007)

P20-18. Diversity of Gag and Nef immunodominant regions in Brazilian HIV-1 B and F1 subtypes
by: Morgado MG, et al.
Published: (2009-10-01)

SERINC5: Its Sensitivity to Nef and Restriction of HIV-1
by: Dai, Weiwei
Published: (2018)

Dose Effects of Recombinant Adenovirus Immunization in Rodents
by: Eric A. Weaver
Published: (2019-10-01)

Adenovirus vectors for manipulating human immune cells
by: Drake, Sian Louise
Published: (2018)

Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.
by: Emily Adland, et al.
Published: (2013-01-01)

Orthoretroviral-like prototype foamy virus gag-pol expression is compatible with viral replication
by: Reh Juliane, et al.
Published: (2011-08-01)

Expression of Gag and Pol from reconstructed HERV-Fc1, associated with multiple sclerosis
by: Nexø Bjørn A, et al.
Published: (2011-10-01)

Pertussis in the Netherlands: an Outbreak Despite High Levels of Immunization with Whole-Cell Vaccine
by: H.E. de Melker, et al.
Published: (1997-06-01)

P16-16. Gag and Nef specific T-cell responses in HIV-1 infected long-term non-progressors in Uganda
by: Kaleebu P, et al.
Published: (2009-10-01)

Characterization of HIV-1 <it>gag</it> and <it>nef</it> in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic
by: Tongo Marcel, et al.
Published: (2013-01-01)

Mouse APOBEC3 interferes with autocatalytic cleavage of murine leukemia virus Pr180gag-pol precursor and inhibits Pr65gag processing.
by: Yoshiyuki Hakata, et al.
Published: (2019-12-01)

Gag-Pol processing during HIV-1 virion maturation: a systems biology approach.
by: Balázs Könnyű, et al.
Published: (2013-01-01)

Is CD47 an innate immune checkpoint for tumor evasion?
by: Xiaojuan Liu, et al.
Published: (2017-01-01)

Immune responses to re-targeted polymer coated adenovirus
by: Onion, David Francis
Published: (2005)

Studies on Cell-Mediated Immunity to Mouse Adenovirus Infection
by: Inada, Toshiki
Published: (2017)

No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
by: Denis R Chopera, et al.
Published: (2013-01-01)